Intestinal Malrotation Foundation Provider Network

Intestinal Malrotation Consortium

The Intestinal Malrotation Foundation has facilitated the cooperation of some of the Nation’s top surgical providers to work together to attain the common goal of best-in-class clinical diagnostics, intervention and follow-through care for patients with intestinal malrotation (IM). The goal of the Intestinal Malrotation Consortium is to improve upon the outcomes of an intestinal malrotation diagnosis, a life-threatening birth defect that has largely been unheeded since the first clear description of the embryological process behind IM was published in 1898. Until the recent establishment of the Intestinal Malrotation Consortium, there have been few options for care for those with IM nor has there been a team of collaborative providers who value best-practice and patient choice for the clinical management of IM. Those on a path for answers can now consult the IMF website to locate providers who know and understand best-practice in clinical care for IM. In addition, the ability for the independent discovery of engaged IM providers will allow for improved patient access to geographically proximal care. The willingness of the consortium providers to collaborate in the best interest of IM patient needs is an incredible commitment and contribution of care to the intestinal malrotation community that has long been overlooked. Interest in the consortium is already expanding and we hope to continue to add additional providers to this mission of Hope for the future of IM patient care.

Providers

Patrick Delaplain, MD

  • Pediatric Surgeon, Texas Children’s Hospital
  • Assistant Professor Baylor College of Medicine

ptdelapl@texaschildrens.org

Read Bio
Dr. Patrick Delaplain is a surgeon at Texas Children’s Hospital who provides care in all aspects of neonatal and pediatric surgery. His specific clinical interests are in colorectal conditions of childhood and adolescence (e.g., Hirschsprung’s Disease), congenital anorectal and pelvic malformations, and diseases of the esophagus and airway. Board certified in critical care, he is also dedicated to providing exceptional surgical care for critically ill children with complex conditions. Dr. Delaplain has an extensive research background with experience in outcomes research, basic science, large database studies, metanalyses, systematic reviews and multi-center trials. He has a special interest in infections as they relate to surgical diseases, trauma and diseases of the critically ill.

James Dunn, MD

  • Pediatric Surgery, Stanford Medical Children’s Health
jdunn2@stanford.edu
Read Bio

Dr. Dunn obtained his B.S. degree in Biology and Chemical Engineering from the California Institute of Technology and his M.D. and Ph.D. degrees from Harvard and Massachusetts Institute of Technology. He trained in General Surgery at the UCLA School of Medicine and in Pediatric Surgery at the Riley Hospital for Children in Indianapolis. He was the Professor and Chief of Pediatric Surgery at UCLA, with a joint appointment in the Department of Bioengineering until 2016. Dr. Dunn served as the Susan B. Ford Surgeon-in-Chief at the Lucile Packard Children’s Hospital from 2016 to 2022. He is the John A. and Cynthia Fry Gunn Director of Pediatric Surgery, and Professor of Surgery and Bioengineering at the Stanford School of Medicine. His research effort is focused on developing new therapies for patients with short bowel syndrome, including an intestinal lengthening device that is currently in clinical trial.

Eunice Huang, MD, MS, FACS, FAAP

  • Monroe Carrell Jr. Children’s Hospital at Vanderbilt
  • Associate Surgeon-in-Chief

eunice.huang@vumc.org

Read Bio
Chief Surgical Quality and Innovations Officers, Vice Chair for Surgical Quality and Patient Safety, Section of Surgical Sciences, Vice Chair of Clinical Services, Department of Pediatric Surgery and Associate Pediatric Surgery Program Director

Dr. Huang joined Monroe Carell Jr. Children’s Hospital at Vanderbilt’s surgical faculty in the Department of Pediatric Surgery from her previous position as Associate Division Chief, Division of Pediatric Surgery, and Professor of Surgery and Pediatrics, Department of Surgery, at the University of Tennessee Health Science Center, Memphis, TN. A major focus of her research and clinical interest is improving and standardizing processes to increase effectiveness, efficiency and consistency of care for common pediatric surgical diseases.

Mark Puder, MD, PhD

  • Boston Children’s Hospital
  • Professor of Surgery, Harvard Medical School

mark.puder@childrens.harvard.edu

Read Bio

Mark Puder M.D., PhD is Professor of Surgery at Harvard Medical School and holds the William E. Ladd Chair at Boston Children’s Hospital. He is a leading expert in the field of fatty acid metabolism as it relates to hepatic disease in children and in angiogenesis as it relates to lung growth. The primary work in his laboratory is the study of parenteral nutrition and its toxic effects on the liver.

Through a variety of laboratory investigations within the Puder lab, several approaches for prevention of the liver injury have emerged. One therapy involves the replacement of the lipid emulsion with a second less toxic emulsion that is based on omega 3 fatty acids. This was made available for compassionate use by the FDA to over 300 patients at Boston Children’s Hospital and has received FDA approval. This has reduced the mortality from this disease at Boston Children’s hospital and is now being used in over 100 institutions in the United States and now worldwide. Prior to its use, the main treatment for this fatal complication was extreme lipid reduction, liver or multivisceral transplants.

SUPPORT OUR CAUSE

The Intestinal Malrotation Foundation operates exclusively on fundraising efforts and donations. Please share your support for our cause by donating.
All donations are made over a secure network.